|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:TCR2_Therapeutics
|
|
gptkbp:biotech_funding
|
public offerings
|
|
gptkbp:biotech_sector
|
immuno-oncology
|
|
gptkbp:business_model
|
biotech startup
|
|
gptkbp:can_lead_to
|
TCR-T cell therapy for solid tumors
|
|
gptkbp:ceo
|
Dr. Garry M. Nolan
|
|
gptkbp:clinical_trial
|
ongoing
Phase 1
Phase 2
TCR-T cell therapy
various cancers
monitored closely
evaluate safety and efficacy
open-label study
data analysis ongoing
analyzed regularly
promising outcomes
ongoing oversight
multiple sites in the US
|
|
gptkbp:clinical_trial_design_phase
|
adaptive design
|
|
gptkbp:clinical_trial_endpoints
|
primary and secondary endpoints.
|
|
gptkbp:clinical_trial_patient_eligibility
|
specific criteria
|
|
gptkbp:clinical_trial_phase1
|
completed
|
|
gptkbp:clinical_trial_phase2
|
in progress
|
|
gptkbp:clinical_trial_phase3
|
planned
|
|
gptkbp:clinical_trial_results_phase1
|
positive results
|
|
gptkbp:clinical_trial_results_phase2
|
awaiting results
|
|
gptkbp:collaboration
|
gptkb:National_Institutes_of_Health
|
|
gptkbp:collaborations
|
gptkb:MD_Anderson_Cancer_Center
gptkb:Partnerships
academic institutions
|
|
gptkbp:collaborator
|
gptkb:University_of_Pennsylvania
|
|
gptkbp:focus
|
T cell receptor therapy
|
|
gptkbp:founded
|
gptkb:2014
|
|
gptkbp:founder
|
Dr. Pavan Reddy
|
|
gptkbp:funding
|
gptkb:Series_B
government grants
|
|
gptkbp:has_advisory_board
|
composed of industry experts
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
TCR Therapeutics
|
|
gptkbp:innovation
|
advancing T cell therapies
|
|
gptkbp:instruction_set
|
TCR therapies
|
|
gptkbp:investment
|
gptkb:venture_capital
gptkb:Orbi_Med_Advisors
$100 million
active engagement
|
|
gptkbp:investment_focus
|
oncology market
|
|
gptkbp:is_a_platform_for
|
TCR discovery platform
|
|
gptkbp:mission
|
develop innovative T cell therapies
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Partnerships
biopharmaceutical companies
|
|
gptkbp:patient_population
|
cancer patients
|
|
gptkbp:product
|
TCR-T cell therapy
|
|
gptkbp:publication
|
peer-reviewed journals
|
|
gptkbp:regulatory_body
|
gptkb:FDA
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
|
|
gptkbp:research
|
focused on TCR technology
|
|
gptkbp:research_areas
|
oncology
personalized medicine
ongoing research
|
|
gptkbp:research_focus
|
gptkb:immunotherapy
T cell engineering
|
|
gptkbp:research_funding_source
|
private investors
|
|
gptkbp:stock_symbol
|
TCRR
|
|
gptkbp:targets
|
gptkb:Oncology
|
|
gptkbp:technology
|
TCR-engineered T cells
|
|
gptkbp:therapeutic_efficacy
|
under investigation
|
|
gptkbp:therapeutic_pipeline
|
diverse candidates
|
|
gptkbp:therapeutic_strategy
|
targeting tumor antigens
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.tcrtherapeutics.com
|
|
gptkbp:bfsParent
|
gptkb:TCR_China
|
|
gptkbp:bfsLayer
|
6
|